Amarin (AMRN)
(Delayed Data from NSDQ)
$0.78 USD
0.00 (-0.11%)
Updated Jul 24, 2024 04:00 PM ET
After-Market: $0.78 0.00 (-0.56%) 7:58 PM ET
4-Sell of 5 4
D Value D Growth A Momentum D VGM
Brokerage Reports
0 items in cart
Amarin Corporation PLC [AMRN]
Reports for Purchase
Showing records 261 - 280 ( 361 total )
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of December 16
Provider: WEDBUSH SECURITIES INC.
Analyst: MARAI C
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Fifth Time''s a Charm?; What''s at Stake Entering NCE Week; Reiterate NEUTRAL
Provider: WEDBUSH SECURITIES INC.
Analyst: FELT A
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Sales Force Hiring and $100MM Financing; ''520 (ANCHOR) Allowance a Consolation for Investors; Reiterate NEUTRAL
Provider: WEDBUSH SECURITIES INC.
Analyst: FELT A
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Vascepa Patent Tracker: ''247 (MARINE Family) Notice of Allowance.
Provider: WEDBUSH SECURITIES INC.
Analyst: FELT A
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Vascepa Patent Tracker - ''775 NOA; Reiterate NEUTRAL
Provider: WEDBUSH SECURITIES INC.
Analyst: FELT A
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of November
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Moving Forward with Commercialization and Hopeful that NCE Clarity Brings Strategic Deal; Reiterate NEUTRAL
Provider: WEDBUSH SECURITIES INC.
Analyst: FELT A
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
NCE and M&A: Potential Implications; Reiterate NEUTRAL
Provider: WEDBUSH SECURITIES INC.
Analyst: FELT A
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Downgrade to NEUTRAL; Stepping Aside as Diminishing Probability of a Super-Sized Buyout Shifts Risk/Reward Ahead of Looming October Deadline
Provider: WEDBUSH SECURITIES INC.
Analyst: FELT A
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
NCE Decision Not Expected in Upcoming Orange Book Update; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: FELT A
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Vascepa NCE Determination by the FDA Delayed
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
No It''s Not An Echo, Another Patent for Vascepa
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of September 9, 2012
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L